Pulmonary artery stiffening is an early driver of pulmonary hypertension

June 02, 2016

Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung. Pulmonary hypertension is caused by a variety of factors, and patient prognosis often depends on the underlying cause. Increased stiffness of pulmonary arteries has been linked to increased mortality in patients with pulmonary hypertension, but it is not clear how stiffness develops or drives worsening of disease. In this issue of JCI Insight, a team led by Laura Fredenburgh of Brigham and Women's Hospital shows that alterations in pulmonary arterial stiffness occur early during disease and promote vascular remodeling by altering signaling mediated by prostaglandins, a class of hormones that regulate inflammation, smooth muscle contraction, and vasoconstrictoin. Using very high-resolution microscopy, Frendenburgh and colleagues detected vascular matrix stiffening in early stages of pulmonary hypertension in both humans and experimental animal models. Pulmonary artery smooth muscle cells grown on matrices with enhanced stiffness exhibited increased proliferation, contraction, and production of matrix proteins. Additionally, the stiff matrix reduced production of a class of prostaglandins that are known to protect against vascular remodeling. Importantly, in a rat model, treatment with a prostaglandin analog reduced pulmonary arterial stiffening and attenuated pulmonary hypertension. The results of this study reveal pulmonary arterial stiffening as an early driver of pulmonary hypertension.
-end-
TITLE: Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension

AUTHOR CONTACT: Laura Fredenburgh
Brigham and Women's Hospital
Email: lfredenburgh@rics.bwh.harvard.edu

View this article at:http://insight.jci.org/articles/view/86987?key=398ec5c1fa8855ce45b4

JCI Insight is the newest publication from the American Society of Clinical Investigation, a nonprofit honor organization of physician-scientists. JCI Insight is dedicated to publishing a range of translational biomedical research with an emphasis on rigorous experimental methods and data reporting. All articles published in JCI Insight are freely available at the time of publication. For more information about JCI Insight and all of the latest articles go to http://www.insight.jci.org.

JCI Journals

Related Pulmonary Hypertension Articles from Brightsurf:

New virtual screening tool eases, accelerates routine diagnosis of pulmonary hypertension
The COVID-19 pandemic has increasing numbers of doctors caring for patients virtually.

Adding another dimension to a cell culture model for pulmonary arterial hypertension
Pulmonary arterial hypertension is a rare disease in which excessive proliferation of the cells of pulmonary arterial walls obstructs the blood flow in the lungs.

Casting a wider net to catch more cases of pulmonary hypertension
Investigators took an evidence-based approach to determine the lower end of the risk spectrum for PH based on pulmonary vascular resistance (PVR), which is resistance against blood flow from the pulmonary artery to the lungs.

Fusion protein holds promise for treating pulmonary arterial hypertension
In a paper published in Science Translational Medicine, researchers illuminate the underlying biological pathways that may lead to vessel destruction in pulmonary arterial hypertension.

New technical approach can enhance diagnosis of pulmonary hypertension
The management and prognosis of pulmonary hypertension heavily relies on whether the pathology is localized in pulmonary arteries or veins.

LSU Health study suggests nicotine exposure alone leads to pulmonary hypertension
A study conducted at LSU Health New Orleans has shown for the first time that chronic exposure to inhaled nicotine alone increases blood pressure in both the body's general circulation and in the lungs that can lead to pulmonary hypertension.

Specific gut bacteria may be associated with pulmonary arterial hypertension
Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs.

Advancing an oral drug for pulmonary arterial hypertension
With a protein drug grown in the leaves of lettuce plants, the University of Pennsylvania's Henry Daniell and colleagues hope to provide new treatment options for patients with pulmonary arterial hypertension, a rare but deadly disease.

Antiarrhythmic drug identified as potential treatment for pulmonary arterial hypertension
High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs.

Pulmonary arterial hypertension targeted for new treatment by Sheffield scientists
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).

Read More: Pulmonary Hypertension News and Pulmonary Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.